Sol-Gel Technologies Ltd. announced on September 4, 2025, that Health Canada approved EPSOLAY® (benzoyl peroxide, 5%, cream) on August 27, 2025. EPSOLAY is indicated for the treatment of inflammatory lesions of rosacea in adults.
This regulatory approval marks a significant expansion for Sol-Gel's commercialized products into the Canadian market. EPSOLAY utilizes a proprietary, patented technology to encapsulate benzoyl peroxide within silica-based microcapsules for controlled release.
The approval in Canada adds to the product's global presence and represents a positive step in leveraging Sol-Gel's dermatology portfolio. This development supports the company's strategy of commercializing or partnering drug products for skin diseases.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.